An eu drug authorization database is a consolidated platform that lets pharmaceutical professionals search marketing authorizations across multiple countries from a single interface. Instead of navigating dozens of national registries in different languages, you query one system and receive structured results covering brand names, marketing authorization holders (MAHs), active ingredients, and ATC codes across 50+ markets. For teams in regulatory affairs, business development, import/export, and market access, this capability eliminates weeks of fragmented research and turns raw authorization records into competitive intelligence.

An EU drug authorization database is a searchable data platform that aggregates marketing authorization records from European and international pharmaceutical markets into one consolidated view. It answers a question that sounds simple but is operationally complex: which medicines are authorized in which countries, under which brand names, by which companies, and containing which active ingredients?

The complexity arises because the European pharmaceutical market is not a single market. A product authorized in France may carry a different brand name in Poland, be held by a different MAH in Turkey, and be entirely absent from the German market. The same active ingredient may appear in 15 countries under 12 different proprietary names. Without a consolidated european medicine database, answering cross-border questions requires visiting individual national agency websites, each with its own language, data format, and search limitations.

“The biggest challenge in international pharmaceutical research is not finding data. The data exists. The challenge is connecting it,” notes Dr. Klaus Menges, a regulatory affairs consultant with 20 years of experience in EU market access. “When you can see authorization records from 50 countries on one screen, patterns become visible that would take weeks to identify manually.”

For professionals working across borders, an EU drug authorization database serves as the operational backbone for four core workflows:

• Market mapping — Determine which products exist in which countries and who holds the authorization
• Import sourcing — Locate authorized products abroad when domestic supply is unavailable or discontinued
• Regulatory referencing — Identify reference products and well-established use evidence across EU jurisdictions
• Competitive analysis — Map competitors by country, active ingredient, ATC code, and therapeutic area

Data Scope: What the EU Drug Authorization Database Contains

The pharmazie.com european medicine database contains more than 120,000 international pharmaceutical products across 50+ countries. Coverage includes all EU member states, EEA countries, Switzerland, the United Kingdom, Turkey, and selected markets in the Middle East, Asia, and the Americas. This scope goes well beyond what any single national registry or even the EMA database provides.

Each product record is structured around searchable, standardized fields:

The Active Pharmaceutical Ingredient Database

The active pharmaceutical ingredient database within pharmazie.com is a comprehensive registry of every active substance used in authorized medicines worldwide. Each ingredient entry includes all internationally recognized naming conventions: INN (International Nonproprietary Name), BAN (British Approved Name), USAN (United States Adopted Name), and WHO designations. This is not a subset — it covers the full global nomenclature landscape.

Beyond nomenclature, every active ingredient record links to its chemical group, pharmacological classification, and every brand name product containing that ingredient, organized by country. If you search for a single active substance, you immediately see the complete international product landscape built around it — which countries authorize products with that ingredient, under which brand names, and held by which MAHs.

This level of cross-referencing is what transforms a simple name lookup into an atc code database international research tool. Starting from an ATC hierarchy level, you can drill down to individual substances and then fan out to every product in every country — all within the same interface.

API Access for Programmatic Integration

All data within the EU drug authorization database is accessible via REST API. This allows regulatory information systems, ERP platforms, and custom analytics tools to pull authorization data programmatically. Common integration scenarios include automated market surveillance dashboards, batch lookups for portfolio analysis, and real-time availability checks embedded in procurement workflows. As real-world evidence gains importance — EMA’s DARWIN EU network has grown to 32 data partners covering 188 million patients across 16 countries — programmatic access to authorization data becomes essential for connecting regulatory records with clinical evidence.

How Cross-Linking Creates Intelligence

Raw authorization records become actionable intelligence when they are connected across datasets. The pharmazie.com platform cross-links its 25+ integrated databases so that every search opens multiple investigative paths. This architecture is the foundation of the Iceberg Search (Eisbergsuche): one query surfaces results across all connected datasets simultaneously, revealing connections that would remain invisible in isolated databases.

A typical navigation pattern for researching drug availability europe by country works as follows:

1. Search an active ingredient — Enter “Isradipine” and retrieve all products containing this substance across 50+ countries
2. Review brand name variations — See that Isradipine is marketed as DynaCirc in Belgium, Icaz in France, and Lomir in Italy, Poland, and Turkey
3. Inspect MAH details — Click any product to view the marketing authorization holder, dosage forms, strengths, and authorization status
4. Navigate the ATC hierarchy — Move up to C08CA (Dihydropyridine derivatives) to identify therapeutic alternatives such as Amlodipine (C08CA01) or Nifedipine (C08CA05)
5. Identify market gaps — Spot countries where the substance is authorized versus countries where no product exists
6. Cross-reference German data — Link to shortage records, ABDA data, pricing, and the discontinued products archive

The cross-linking architecture means that the EU drug authorization database does not exist in isolation. International product records connect to German drug data (based on the ABDA-Artikelstamm). German data connects to shortage monitoring. Shortage data connects back to the EU database for sourcing alternatives. The discontinued products archive provides historical context for products that have left markets. A single search query can answer questions that would otherwise require consulting five or six separate systems.

Practical Example: Mapping Isradipine Across Europe

Consider a regulatory affairs team assessing Isradipine for a potential generic filing. A search in pharmazie.com reveals that no product containing Isradipine is currently marketed in Germany. The EU database shows authorized products in Belgium (DynaCirc), France (Icaz), Italy (Lomir), Poland (Lomir), and Turkey (Lomir). Each record includes the local MAH, available strengths, dosage forms, and authorization details.

Three teams derive three different outputs from this single search:

• Regulatory affairs identifies reference product candidates in Belgium and France for a generic application under Article 10 of Directive 2001/83/EC
• Business development sees a market gap in Germany — a substance authorized in multiple EU member states but absent from Germany’s largest pharmaceutical market
• Import/export identifies sourcing countries for potential Article 73.3 imports should clinical demand arise

EU Drug Authorization Database Use Cases by Team

Regulatory Affairs

Regulatory professionals rely on international authorization data at every stage of the product lifecycle. The most common use cases include:

• Reference product identification — Locate the originator product across EU markets for generic or biosimilar applications, including markets where the reference product is still authorized even if withdrawn domestically
• Well-established use documentation — Demonstrate that an active substance has been in medicinal use for at least 10 years within the EU by compiling authorization records from multiple member states
• Discontinued product investigation — Use the pharmazie.com discontinued products archive to determine whether a withdrawal was safety-related or purely commercial, a critical distinction for Article 10 applications
• Variation benchmarking — Compare how the same product is authorized across jurisdictions in terms of strengths, indications, and formulations to support variation submissions
• Adapting to the new EU Pharma Package — Following the political agreement on the EU pharmaceutical legislation reform reached in December 2025, regulatory teams need cross-border authorization data to prepare for the transition period through 2028

“We used to spend two to three days researching whether a reference product was still authorized somewhere in Europe. Now it takes five minutes,” reports a regulatory affairs lead at a mid-sized German generics company. “The time savings are significant, but the real value is completeness. We no longer worry about missing a market.”

Business Development and Market Access

The EU drug authorization database functions as a market intelligence tool when used strategically. Business development teams leverage it to:

• Identify white spaces — Products authorized in multiple EU countries but absent from a target market represent licensing or launch opportunities
• Locate licensing partners — The MAH in a source country is the natural first contact for in-licensing discussions; the eu marketing authorization holder database provides this information directly
• Map competitive landscapes — Filter by ATC code and country to see exactly which competitors operate in each market, with which products, and at which strengths
• Track market entry signals — New authorizations in adjacent markets serve as early indicators of competitive moves

Import/Export and Parallel Trade

For pharmaceutical wholesalers and parallel importers, the database serves as a sourcing and compliance tool:

• Article 73.3 import sourcing — When a product is unavailable in Germany, identify authorized equivalents in other EU/EEA countries for emergency import under German pharmaceutical law
• Cross-border price analysis — Combine international authorization data with pricing information to identify parallel import opportunities where price differentials justify trade
• Documentation preparation — Gather the authorization details (MAH, product name, country, dosage form) required for parallel import license applications
• Alternative sourcing during shortages — The direct link between the shortage database and the EU authorization database means that when a German product becomes unavailable, international alternatives surface automatically

Comparing EU Drug Databases: EMA vs. National vs. Consolidated

Not all european medicine database search tools cover the same ground. The differences are substantial, and choosing the wrong source can create critical blind spots in your research.

Why the EMA Database Is Not Enough

The European Medicines Agency (EMA) medicines database is an authoritative source, but it only covers centrally authorized products — medicines that received a single EU-wide marketing authorization through the centralized procedure. In 2025, EMA recommended just 104 medicines for authorization, including 38 new active substances and 41 biosimilars. This represents a small fraction of the medicines available in Europe. The vast majority of pharmaceutical products are authorized nationally, through national procedures, mutual recognition procedures (MRP), or decentralized procedures (DCP). These nationally authorized products do not appear in the EMA database at all.

This means that any professional researching drug registered which countries europe using only the EMA database will miss most of the market. A generic medicine authorized through MRP in 15 EU member states, a locally marketed branded product in Turkey, or a parallel-imported specialty in the UK — none of these would appear in EMA search results.

The National Database Problem

National databases operated by agencies such as France’s ANSM, Germany’s BfArM, or the UK’s MHRA are comprehensive for their respective markets but present two fundamental limitations for cross-border research:

• Language barriers — Each database operates in its national language, making systematic research across 10 or 20 countries impractical without multilingual staff
• No cross-linking — National databases do not connect to each other. To determine whether the same active ingredient is authorized in Belgium, Spain, and Poland, you must search three separate systems with three different interfaces

The pharmazie.com EU database resolves both problems by consolidating nationally and centrally authorized products from 50+ countries into a single, cross-linked interface. Every product record connects to the active pharmaceutical ingredient database, the ATC classification hierarchy, German drug data (ABDA-Artikelstamm), shortage monitoring, and the discontinued products archive. This consolidation is what transforms isolated records into pharmaceutical product availability europe intelligence.

Frequently Asked Questions

What is the difference between the EMA database and a consolidated EU drug authorization database?

The EMA medicines database only contains centrally authorized products — medicines that received a single EU-wide marketing authorization. In 2025, EMA recommended 104 medicines for authorization, whereas tens of thousands of products are authorized nationally across EU member states. A consolidated EU drug authorization database like pharmazie.com includes both centrally and nationally authorized products from 50+ countries, covering national procedures, mutual recognition procedures (MRP), and decentralized procedures (DCP). This means it captures the full market picture rather than a subset.

How many countries does the pharmazie.com EU drug authorization database cover?

The pharmazie.com EU database covers more than 50 countries, including all EU member states, EEA countries, Switzerland, the United Kingdom, Turkey, and selected markets in the Middle East, Asia, and the Americas. It contains over 120,000 international pharmaceutical products with structured data on brand names, marketing authorization holders, active ingredients, ATC codes, dosage forms, and strengths.

Can I search for an active ingredient and see all countries where it is authorized?

Yes. The active pharmaceutical ingredient database allows you to search any substance by INN, BAN, USAN, or WHO name and immediately see every brand name product containing that ingredient, organized by country. This makes it possible to assess the full geographic footprint of a substance in a single query, identify market gaps, and locate potential sourcing or licensing partners across jurisdictions.

Does the database include products that have been discontinued or withdrawn?

Yes. The pharmazie.com platform maintains a discontinued products archive that records medicines withdrawn from markets. Each entry includes the reason for withdrawal where available, which is critical for regulatory professionals who need to distinguish between safety-related withdrawals and commercial exits. This archive is cross-linked with the active EU authorization data, enabling complete lifecycle analysis of any product or substance.

Is API access available for the EU drug authorization database?

Yes. The pharmazie.com EU drug authorization database offers full REST API access, supporting JSON, CSV, XML, and Excel formats. This enables integration with ERP systems, regulatory information management platforms, market surveillance dashboards, and custom analytics tools. Common use cases include automated batch lookups for portfolio analysis, real-time availability monitoring, and programmatic data feeds for procurement systems. Contact the pharmazie.com team for API documentation and integration support.